GSK Files Lawsuit Against Pfizer for RSV Vaccine Patent Infringement

GlaxoSmithKline (GSK) has filed a lawsuit against Pfizer, alleging that Pfizer's RSV vaccine, Abrysvo, infringes on GSK's patents for its own RSV shot, Arexvy. GSK claims that Pfizer knowingly used vaccine ingredients developed by GSK without permission, including recombinant RSV antigens and RSV F protein compositions. GSK also noted that its vaccine was in development seven years prior to Pfizer's. Both Pfizer and GSK's vaccines were approved for patients 60 years or older by the FDA in May.